Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, today announced that the topline phase 2 study data of masupirdine (SUVN-502) to be presented at AAIC- 2019 at Los Angeles on July 17, 2019 is delayed.
This phase 2, Proof-of-Concept (POC) study is a randomized, double-blind, placebocontrolled study is evaluating the efficacy and safety of two doses of masupirdine (SUVN-502) in moderate Alzheimer's Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer's disease patients.
There is an unanticipated delay in the masupirdine (SUVN-502) proof-of-concept phase 2 study outcome data availability in time for AAIC-2019 due to technical reasons.
Hence this study outcome results will not be presented at AAIC-2019 as originally planned.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.257.05 as compared to the previous close of Rs. 257.3. The total number of shares traded during the day was 22788 in over 625 trades.
The stock hit an intraday high of Rs. 264.3 and intraday low of 253.7. The net turnover during the day was Rs. 5884089.